Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [3] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [3] Financial Results Announcement - Esperion will report its fourth quarter and full year 2025 financial results on March 10, 2026, before the market opens [1] - Following the financial results release, management will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates [1] Webcast Information - A live audio webcast will be accessible on the investor and media section of the Esperion website, with a replay available approximately two hours after the call [2] - The webcast replay will be archived on the company's website for about 90 days [2] Market Position and Pipeline - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning it as a partner-of-choice for global innovators seeking U.S. market access [4] - The company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [4]